8 false false false false false false false false false false true false false false false false false No description of principal activity 2022-04-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 9352402 2022-04-01 2023-03-31 9352402 2023-03-31 9352402 2022-03-31 9352402 2021-04-01 2022-03-31 9352402 2022-03-31 9352402 2021-03-31 9352402 bus:RegisteredOffice 2022-04-01 2023-03-31 9352402 bus:LeadAgentIfApplicable 2022-04-01 2023-03-31 9352402 bus:Director1 2022-04-01 2023-03-31 9352402 bus:Director2 2022-04-01 2023-03-31 9352402 core:WithinOneYear 2023-03-31 9352402 core:WithinOneYear 2022-03-31 9352402 core:ShareCapital 2023-03-31 9352402 core:ShareCapital 2022-03-31 9352402 core:RetainedEarningsAccumulatedLosses 2023-03-31 9352402 core:RetainedEarningsAccumulatedLosses 2022-03-31 9352402 bus:SmallEntities 2022-04-01 2023-03-31 9352402 bus:AuditExempt-NoAccountantsReport 2022-04-01 2023-03-31 9352402 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 9352402 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 9352402 bus:FullAccounts 2022-04-01 2023-03-31
COMPANY REGISTRATION NUMBER: 9352402
EUDELO MEDICAL LIMITED
FILLETED UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 March 2023
EUDELO MEDICAL LIMITED
FINANCIAL STATEMENTS
YEAR ENDED 31 MARCH 2023
Contents
Page
Officers and professional advisers
1
Statement of financial position
2
Notes to the financial statements
3
EUDELO MEDICAL LIMITED
OFFICERS AND PROFESSIONAL ADVISERS
The board of directors
Dr J Williams
Dr S Williams
Registered office
63 Bondway
London
United Kingdom
SW8 1SJ
Accountants
BSG Valentine (UK) LLP
Chartered Accountants
Lynton House
7 - 12 Tavistock Square
London
WC1H 9BQ
EUDELO MEDICAL LIMITED
STATEMENT OF FINANCIAL POSITION
31 March 2023
2023
2022
Note
£
£
£
£
CURRENT ASSETS
Debtors
5
259,937
150,751
Cash at bank and in hand
21,177
9,037
---------
---------
281,114
159,788
CREDITORS: amounts falling due within one year
6
85,659
92,194
---------
---------
NET CURRENT ASSETS
195,455
67,594
---------
--------
TOTAL ASSETS LESS CURRENT LIABILITIES
195,455
67,594
---------
--------
NET ASSETS
195,455
67,594
---------
--------
CAPITAL AND RESERVES
Called up share capital
100
100
Profit and loss account
195,355
67,494
---------
--------
SHAREHOLDERS FUNDS
195,455
67,594
---------
--------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the income statement has not been delivered.
For the year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 29 November 2023 , and are signed on behalf of the board by:
Dr S Williams
Director
Company registration number: 9352402
EUDELO MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 MARCH 2023
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 63 Bondway, London, United Kingdom, SW8 1SJ.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 8 (2022: 8 ).
5. Debtors
2023
2022
£
£
Amounts owed by group undertakings and undertakings in which the company has a participating interest
259,937
150,751
---------
---------
6. Creditors: amounts falling due within one year
2023
2022
£
£
Corporation tax
82,859
89,394
Other creditors
2,800
2,800
--------
--------
85,659
92,194
--------
--------
7. Controlling party
The company is a wholly owned subsidiary of Eudelo Investments Limited , a company incorporated in the United Kingdom. The company was under the control of Eudelo Investments Ltd throughout the current year. Dr S Williams is the managing director and majority shareholder of Eudelo Investments Ltd